Bristol Gate Capital Partners, an investment management company, published its Q4 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. Bristol Gate prioritizes companies with strong free cash flows, disciplined capital allocation, and high dividend growth for superior risk-adjusted returns. These resilient businesses align management interests with shareholders through sustainable dividends. Since late 2022, the market has shifted towards AI leaders, resulting in the fund’s underperformance due to narrow breadth. While the firm invests in data science and AI, the focus remains on high dividend growth companies. Recently, this narrow focus was shifting, supported by the outperformance of the S&P US Dividend Growers, S&P 500 Dividend Aristocrats, and S&P 500 Equal Weight. This market breadth expansion, along with the firm’s Data Science team’s advancements in the Distant Future Model, offers a strong opportunity for investors to buy the strategy and mitigate risks in the current concentrated market. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Bristol Gate Capital Partners US Equity Strategy highlighted Eli Lilly and Company (NYSE:LLY) as one of its leading contributors. Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company headquartered in Indianapolis, Indiana, that develops, manufactures, and markets human pharmaceutical products. On March 27, 2026, Eli Lilly and Company (NYSE:LLY) stock closed at $878.24 per share. One-month return of Eli Lilly and Company (NYSE:LLY) was -13.73%, and its shares gained 6.34% over the past 52 weeks. Eli Lilly and Company (NYSE:LLY) has a market capitalization of $786.041 billion.
Bristol Gate Capital Partners US Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2025 investor letter:
“Eli Lilly and Company (NYSE:LLY) continues to benefit from the strength of its incretin portfolio. During the quarter, LLY reported Q3 results that were ahead of analyst expectations, driven by its GLP-1 franchise (Mounjaro and Zepbound). LLY now commands 58% of the US incretin market, and exited Q3 with 71% of new prescriptions, indicating further market share gains ahead. The strength led management to raise their annual guidance for the year for the third time this year. We believe LLY will carry this strength into 2026 when its oral GLP-1 drug (orforglipron) is expect to hit the market in the Spring. We believe the oral alternative will significantly expand the market globally due to the ease of use (no needle), less complex supply chain (much easier to manufacture and no cold storage chain needed) and lower cost.”
Eli Lilly and Company (NYSE:LLY) ranks 16th on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 137 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the fourth quarter, up from 114 in the previous quarter. Eli Lilly and Company (NYSE:LLY) achieved impressive results in 2025, with revenue increasing by 45% to $65.2 billion, and fourth-quarter revenue growing by 43%. While we acknowledge the risk and potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Eli Lilly and Company (NYSE:LLY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared a list of good stocks to buy. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
